You are here: Industry Insights > stroke

News List

Researchers identify new genetic clues for ‘silent’ strokes pharmatimes
March 29, 2021
New research has discovered genetic clues in people who have had small, ‘silent’ strokes that could enable the development of new treatments for the condition.
The Stroke Association to fund study investigating strokes caused by COVID-19 pharmatimes
February 09, 2021
UK charity The Stroke Association has announced today that it will fund a research study aiming to investigate reports that COVID-19 is causing life-threatening strokes.
Creative Medical Technology Announces Successful Application of ImmCelz Immunotherapy for Stroke americanpharmaceuticalreview
January 06, 2021
Creative Medical Technology Holdings announced positive preclinical data supporting the utilization of its ImmCelz® cell-based immunotherapy for treatment of stroke.
Research highlights benefit of telemedicine for stroke treatment pharmatimes
December 08, 2020
Paramedics could use FaceTime to improve their assessment of stroke symptoms and help quickly and accurately identify stroke patients, according to new research presented at the UK Stroke Forum.
AZ’s Brilinta reduced rate of stroke and death in high-risk subgroup pharmatimes
November 19, 2020
AstraZeneca’s P2Y12 receptor antagonist Brilinta reduced the rate of stroke and death in a prespecified, high-risk subgroup, according to new analysis of the phase III THALES trial.
Brilinta Approved to Reduce Stroke Risk americanpharmaceuticalreview
November 17, 2020
AstraZeneca’s Brilinta (ticagrelor) has been approved in the US to reduce the risk of stroke, a leading cause of disability and death worldwide, in patients with acute ischemic stroke (National Institutes of Health Stroke Scale score ≤5) or high-risk ...
US green lights AZ’s Brilinta to reduce risk of stroke pharmatimes
November 10, 2020
The US Food and Drug Administration (FDA) has approved AstraZeneca’s Brilinta (ticagrelor) to reduce the risk of stroke in patients with acute ischemic stroke or high-risk transient ischaemic attack (TIA).
Boston Scientific Initiates Trial to Evaluate WATCHMAN FLX as Treatment for Risk of Stroke americanpharmaceuticalreview
November 09, 2020
Boston Scientific has initiated the CHAMPION-AF clinical trial to evaluate the safety and efficacy of the WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device within a broad population of patients with non-valvular atrial fibrillation (NVAF) ...
Brilinta significantly reduced rate of composite of stroke and death in THALES trial pharmaceutical-business-review
July 21, 2020
Detailed results from the positive Phase III THALES trial showed AstraZeneca’s Brilinta (ticagrelor) 90mg used twice daily and taken with daily aspirin for 30 days, reduced the rate of the primary composite endpoint of stroke and death by 17% (HR 0.83 ...
Creative Medical Technology Completes AmnioStem Preclinical Studies americanpharmaceuticalreview
July 21, 2020
Creative Medical Technology announced completion of preclinical studies assessing the anti-inflammatory and neuroregenerative activities of AmnioStem™.

Previous page 1 2 3 4 5 6 7 8 9 10 Next page